226 related articles for article (PubMed ID: 16450142)
21. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.
Abdul Wahid SF; Ismail NA; Mohd-Idris MR; Jamaluddin FW; Tumian N; Sze-Wei EY; Muhammad N; Nai ML
Stem Cells Dev; 2014 Nov; 23(21):2535-52. PubMed ID: 25072307
[TBL] [Abstract][Full Text] [Related]
22. Human CD80/IL2 lentivirus transduced acute myeloid leukaemia cells enhance cytolytic activity in vitro in spite of an increase in regulatory CD4+ T cells in a subset of cultures.
Ingram W; Kordasti S; Chan L; Barber LD; Tye GJ; Hardwick N; Mufti GJ; Farzaneh F
Cancer Immunol Immunother; 2009 Oct; 58(10):1679-90. PubMed ID: 19283381
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy in leukaemia.
Mu X; Chen C; Dong L; Kang Z; Sun Z; Chen X; Zheng J; Zhang Y
Acta Biochim Biophys Sin (Shanghai); 2023 Jun; 55(6):974-987. PubMed ID: 37272727
[TBL] [Abstract][Full Text] [Related]
24. Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct.
Lazarus HM; Rowe JM
Leukemia; 2006 Oct; 20(10):1673-82. PubMed ID: 16871280
[TBL] [Abstract][Full Text] [Related]
25. Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.
Smits EL; Lee C; Hardwick N; Brooks S; Van Tendeloo VF; Orchard K; Guinn BA
Cancer Immunol Immunother; 2011 Jun; 60(6):757-69. PubMed ID: 21519825
[TBL] [Abstract][Full Text] [Related]
26. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine.
Cheuk AT; Guinn BA
Front Biosci; 2008 Jan; 13():2022-9. PubMed ID: 17981688
[TBL] [Abstract][Full Text] [Related]
28. Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect.
Murdock HM; Ho VT; Garcia JS
Front Immunol; 2024; 15():1359113. PubMed ID: 38571944
[TBL] [Abstract][Full Text] [Related]
29. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy prospects for acute myeloid leukaemia.
Barrett AJ; Le Blanc K
Clin Exp Immunol; 2010 Aug; 161(2):223-32. PubMed ID: 20529084
[TBL] [Abstract][Full Text] [Related]
31. Novel strategies to prevent relapse after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes.
Kekre N; Koreth J
Curr Opin Hematol; 2015 Mar; 22(2):116-22. PubMed ID: 25575033
[TBL] [Abstract][Full Text] [Related]
32. A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation.
Ringdén O; Erkers T; Aschan J; Garming-Legert K; Le Blanc K; Hägglund H; Omazic B; Svenberg P; Dahllöf G; Mattsson J; Ljungman P; Remberger M
J Intern Med; 2013 Aug; 274(2):153-62. PubMed ID: 23432209
[TBL] [Abstract][Full Text] [Related]
33. Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.
Ringdén O; Labopin M; Schmid C; Sadeghi B; Polge E; Tischer J; Ganser A; Michallet M; Kanz L; Schwerdtfeger R; Nagler A; Mohty M;
Br J Haematol; 2017 Feb; 176(3):431-439. PubMed ID: 27879990
[TBL] [Abstract][Full Text] [Related]
34. Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.
Malladi RK; Peniket AJ; Norton AE; Campbell AJ; Collins GP; Samol J; Eagleton H; Miller E; Morgenstern G; Jones J; Keen-Mcguire A; Barnardo M; Littlewood TJ
Eur J Haematol; 2004 Aug; 73(2):85-92. PubMed ID: 15245506
[TBL] [Abstract][Full Text] [Related]
35. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
Brissot E; Labopin M; Stelljes M; Ehninger G; Schwerdtfeger R; Finke J; Kolb HJ; Ganser A; Schäfer-Eckart K; Zander AR; Bunjes D; Mielke S; Bethge WA; Milpied N; Kalhs P; Blau IW; Kröger N; Vitek A; Gramatzki M; Holler E; Schmid C; Esteve J; Mohty M; Nagler A
J Hematol Oncol; 2017 Jun; 10(1):130. PubMed ID: 28646908
[TBL] [Abstract][Full Text] [Related]
36. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
Grigg AP; Gibson J; Bardy PG; Reynolds J; Shuttleworth P; Koelmeyer RL; Szer J; Roberts AW; To LB; Kennedy G; Bradstock KF
Biol Blood Marrow Transplant; 2007 May; 13(5):560-7. PubMed ID: 17448915
[TBL] [Abstract][Full Text] [Related]
37. Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients.
Cho BS; Yahng SA; Min GJ; Park S; Park SS; Shin SH; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Transplant Cell Ther; 2021 Sep; 27(9):774.e1-774.e12. PubMed ID: 34082159
[TBL] [Abstract][Full Text] [Related]
38. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines.
Dunussi-Joannopoulos K; Dranoff G; Weinstein HJ; Ferrara JL; Bierer BE; Croop JM
Blood; 1998 Jan; 91(1):222-30. PubMed ID: 9414288
[TBL] [Abstract][Full Text] [Related]
39. Acute myeloid leukaemia and the immune system: implications for immunotherapy.
Barrett AJ
Br J Haematol; 2020 Jan; 188(1):147-158. PubMed ID: 31782805
[TBL] [Abstract][Full Text] [Related]
40. Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML.
Niederwieser D; Lange T; Cross M; Basara N; Al-Ali H
Best Pract Res Clin Haematol; 2006; 19(4):825-38. PubMed ID: 16997186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
